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Engineering, Drexel University, Philadelphia, PennsylvaniaABSTRACT The serotonin 5-HT3 receptor (5-HT3R) is a member of the Cys-loop ligand-gated ion channel family. We used
a combination of site-directed mutagenesis, homology modeling, and ligand-docking simulations to analyze antagonist-receptor
interactions. Mutation of E236, which is near loop C of the binding site, to aspartate prevents expression of the receptor on the cell
surface, and no speciﬁc ligand binding can be detected. On the other hand, mutation to glutamine, asparagine, or alanine
produces receptors that are expressed on the cell surface, but decreases receptor afﬁnity for the competitive antagonist d-tubo-
curarine (dTC) 5-35-fold. The results of a double-mutant cycle analysis employing a panel of dTC analogs to identify speciﬁc
points of interactions between the dTC analogs and E236 are consistent with E236 making a direct physical interaction with
the 12 –OH of dTC. dTC is a rigid molecule of known three-dimensional structure. Together with previous studies linking other
regions of dTC to speciﬁc residues in the binding site, these data allow us to deﬁne the relative spatial arrangement of three
different residues in the ligand-binding site: R92 (loop D), N128 (loop A), and E236 (near loop C). Molecular modeling employing
these distance constraints followed by molecular-dynamics simulations produced a dTC/receptor complex consistent with the
experimental data. The use of the rigid ligands as molecular rulers in conjunction with double-mutant cycle analysis provides
a means of mapping the relative positions of various residues in the ligand-binding site of any ligand-receptor complex, and
thus is a useful tool for delineating the architecture of the binding site.INTRODUCTIONThe serotonin type 3 receptor (5-HT3R) is a member of the
Cys-loop ligand-gated ion channel family, which includes
the muscle and neuronal nicotinic acetylcholine receptors
(AChRs), the glycine receptor (GlyR), and the g-aminobuty-
ric acid type A (GABAAR) and r (GABAArR) receptors
(1,2). Two different subunits, 5-HT3A and 5-HT3B, have
been shown to be present in functional 5-HT3Rs (3). Expres-
sion of the 5-HT3A subunit (4) results in 5-HT-gated chan-
nels with a pharmacology appropriate for 5-HT3Rs.
However, there are some differences between the properties
of the expressed homomeric receptors and 5-HT3Rs in some,
but not all, neurons. The most significant difference is that
the single-channel conductance of the homomeric receptors
is in the subpicosecond range, whereas that of the receptors
in some peripheral (but not central nervous system) neurons
is in the range of 9–19 pS (5).
The 5-HT3B subunit does not form functional receptors
by itself; however, coexpression with the 5-HT3A subunit
produces heteromeric receptors with a single-channel
conductance of 16 pS (6). The expression patterns of the
5-HT3A and 5-HT3B subunits suggest that both 5-HT3A ho-
momers and 5-HT3A/5-HT3B heteromers exist in both the
central and peripheral nervous systems (7). Despite the
differences in their single-channel properties, these two types
of receptors have very similar ligand-binding properties (8).Submitted December 11, 2009, and accepted for publication January 14,
2010.
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0006-3495/10/05/1847/9 $2.00For example, inclusion of the rat 5-HT3B subunit produces
receptors with only an ~2-fold increase in IC50 for d-tubocu-
rarine (dTC) inhibition of currents (9). Thus, 5-HT3A homo-
pentamers are an appropriate model for the structure of the
ligand-binding domain of native 5-HT3Rs, regardless of
whether they are 5-HT3A homomers or 5-HT3A/5-HT3B
heteromers.
Previous studies have used a combination of site-directed
mutagenesis and molecular modeling to probe the architec-
ture of the ligand-binding domain of the 5-HT3R (10–16).
In this approach, the effects of introduced mutations on
ligand binding and/or agonist-elicited currents are used to
identify residues that may play a role in ligand-receptor inter-
actions. The data are then analyzed in terms of a structural
model for the extracellular domain of the receptor con-
structed using the structure of the molluscan acetylcholine
binding protein (AChBP) (17) as the template for modeling,
and the models that are most consistent with the data are then
used to guide further experiments.
In most of these studies, only the effects of receptor muta-
tions were monitored. In this work, we combined the intro-
duction of mutations in the receptor with alterations in ligand
structure to more fully probe ligand-receptor interactions
using double-mutant cycle analysis (18). To take full advan-
tage of the double-mutant cycle analysis, we employed
a panel of ligands with a number of defined small changes
in structure. One ligand that can be altered in a number of
ways is dTC, a competitive antagonist of both AChRs (19)
and 5-HT3Rs (20). dTC has a 1- to 2000-fold higher affinity
for the murine 5-HT3R than the human receptor, and it wasdoi: 10.1016/j.bpj.2010.01.034
1848 Nyce et al.shown that the regions responsible for this species difference
are located in the amino terminal extracellular domain (21).
We subsequently showed that a major determinant for this
difference is located in loop F of the binding site (22). Using
a series of dTC analogs, we demonstrated that the same
regions of dTC that are important for high-affinity binding
to the AChR (23,24) are also important for binding to the
5-HT3R (25). In a subsequent study, we showed that N128
in the 5-HT3R interacted with the 2
0N of dTC, and that
R92 most likely interacted with the 2N of dTC (15).
In this study, we map an additional residue in the putative
ligand-binding site (E236) onto the dTC structure, and then
use the rigid three-dimensional structure of dTC to provide
relative spatial distances between three separate residues in
the ligand-binding domain. These distances then become
spatial restraints in the subsequent modeling process. The
use of a rigid molecular ruler to obtain experimentally
derived spatial positions of residues in the binding site thus
provides a general approach for delineating the architecture
of a portion of the ligand-binding site.FIGURE 1 dTC analogs used in this study.MATERIALS AND METHODS
Molecular biology and transfection
A cDNA clone corresponding to the short form of the murine 5-HT3A
subunit (26) isolated from a neuroblastoma N1E-115 cell line cDNA library
(27) was used in these studies. Site-directed mutagenesis was carried out
using the QuickChange system (Stratagene, La Jolla, CA), and the entire
coding region of the mutant subunit was sequenced to ensure that only the
desired mutation was present. Since the amino terminus of the mature
5-HT3A subunit is unknown, the amino acid numbering system used
here includes the signal sequence and starts from the initial methionine.
tsA201 cells were maintained in Dulbecco’s modified Eagle’s medium con-
taining 10% fetal bovine serum, 100 U/mL penicillin, and 100 U/mL strep-
tomycin. Cultures at 50–60% confluence were transfected with 10 mg
receptor cDNA per 100 mm dish using Fugene transfection reagent (Roche
Diagnostics, Indianapolis, IN). Maximal expression was obtained 36–72 h
after transfection.
Ligand-binding assays
Transfected cells were processed as previously described (15) and
membranes were incubated for 2 h at 37C in 154 mM NaCl, 20 mM Tris-
HCl, pH 7.4, containing the appropriate concentrations of the competing
unlabeled ligand (e.g., dTC) and radioligand ([3H]granisetron, 85 Ci/mmol;
PerkinElmer, Waltham, MA). Binding was terminated by rapid vacuum
filtration onto GF/B filters. Nonspecific binding was defined as that which
was not displaced by 10 mM m-chlorophenyl biguanide. IC50 values for the
various dTC analogs were determined by fitting the data to the following
equation:
q ¼ 1 þ ½1=IC50ÞnÞ
1
(1)
where q is the fractional amount of [3H]granisetron bound in the presence of
the antagonist at concentration [I] compared with that in the absence of
antagonist, IC50 is the concentration of antagonist at which q ¼ 0.5, and
n is the apparent Hill coefficient. Ki values were calculated from the
IC50 values and the Kd for [
3H]granisetron using the Cheng-Prusoff relation
(28):Biophysical Journal 98(9) 1847–1855Ki ¼ IC50
1 þ ð½L=KdÞ
(2)
where [L] is the concentration of [3H]granisetron used to determine the IC50
value in the experiment, and Kd is the dissociation constant for [
3H]granise-
tron. Error estimates of DDGint values calculated from Ki values were
obtained through analysis of propagation of errors (29).
dTC analogs
The structures of the dTC analogs used in this study are shown in Fig. 1.
Two of the compounds—dTC (Sigma, St. Louis, MO) and metocurine
(Diosynth, Chicago, IL)—were obtained commercially, and the others
were obtained from Dr. Steen Pedersen of Baylor University College of
Medicine (23,24). The purity of all compounds was checked by high-perfor-
mance liquid chromatography both before use and after prolonged incuba-
tion with the assay buffers.
Immunoﬂuorescence analysis of receptor
expression
tsA201 cells on poly-L-lysine-coated coverslips were fixed with 4% parafor-
maldehyde in Tris-buffered saline (0.1 M Tris, 154 mM NaCl, pH 7.4) for
45 min, followed by three washes with phosphate-buffered saline (PBS).
Intracellular receptor expression was determined by incubation with PBS
containing 0.1% Triton X-100 for 30 min, and Triton X-100 was omitted
to visualize receptor surface expression. Nonspecific antibody binding was
blocked with 1% bovine serum albumin in PBS for 5 min, followed by incu-
bation with the primary rabbit 5-HT3A polyclonal antibody pAb120 (30) for
90 min. Cells were washed extensively with bovine serum albumin/PBS
before incubation with a secondary antibody blocking buffer containing
10% goat serum (Invitrogen; Carlsbad, CA) in PBS for 10 min. Cells
were incubated with FITC-conjugated goat anti-rabbit IgG (Jackson Immu-
noresearch Laboratories, West Grove, PA) for 90 min, followed by extensive
washing with goat serum/PBS. Stained preparations were mounted and
analyzed using a Nikon PCM 2000 laser-scanning confocal imaging system.
FIGURE 2 Subcellular localization ofWT and mutant 5-HT3Rs. Confocal
images of immunofluorescent-labeled permeabilized and nonpermeabilized
cells expressing WT or E236D 5-HT3Rs are shown. Surface expression is
only visible in nonpermeabilized cells expressingWT 5-HT3Rs. Intracellular
receptor expression ofWT and E236D 5-HT3Rs is observed in permeabilized
cell preparations. No fluorescence is visible in untransfected control cells.
Scale bar: 10 mm.
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transfected tsA201 control cell preparations.
Molecular modeling and ligand docking
A model of the extracellular domain of 5-HT3A pentamers was generated
using MODELLER 9v5 (31,32). The structures of the Aplysia AChBP in
the apo (PDB ID: 2BYN) and methyllycaconitine-bound (PDB ID: BYR)
forms were used as templates because they are representative of the structure
in the resting state and with a small-molecule antagonist bound (both forms
have similar conformations (33)). The sequence alignment between the tem-
plates and 5-HT3A monomers was performed with the SALIGN function of
MODELLER, which uses a variable gap-opening penalty that depends on-
the three-dimensional structure of the template. All five subunits were
modeled simultaneously to ensure structural integrity between subunit inter-
faces, and polar hydrogens were included to allow for main-chain hydrogen
bonding. When additional experimentally derived distance restraints were
included in the modeling process, the distance was harmonically restrained
to be around the specified value 5 a standard deviation of 0.5 A˚. A set of
30–50 models was generated, and ProSA (34) was used to evaluate the
generated models and to identify regions that might need further refinement
by manually adjusting the alignment. The model that was ranked highest by
ProSA was chosen for ligand docking.
Ligand docking was performed using AutoDock4 (35). The scoring func-
tions used in AutoDock can discriminate between near-native and mis-
docked conformations of the ligand, and the conformations of ligands
docked in a binding site agree with bound conformations in crystal structures
of ligand-protein complexes (36). Docking was performed on a 30  30 
40 A˚ grid with a spacing of 0.375 A˚. The size of the grid ensures that the
ligand has sufficient freedom to be docked in all possible orientations but
is not allowed to move far outside of the binding site. We performed 256
separate simulations and chose the one that was most consistent with our
experimentally derived criteria (i.e., 20N of dTC near N128, 2N near R92,
and 12 –OH near E236).
Molecular-dynamics simulations
For molecular-dynamics (MD) simulations, the pentameric 5-HT3A extra-
cellular domain with bound dTC obtained from AutoDock was placed in
a periodic box of approximate dimensions 10 nm  10 nm  10 nm. Coun-
terions were added to provide overall charge neutrality, and ~28,000 water
molecules were added. The simulation system contained ~100,000 atoms.
The protein was modeled with the AMBER parm99SB force field (37)
and dTC was modeled with the AMBER gaff force field (38) with charge
assignment from the AM1-BCC model (39,40). Water molecules were
modeled with the TIP3P force field (41). All simulations were conducted
with NAMD v2.6 (42) with a time step of 2 fs. The simulations were run
at a constant temperature of 310 K and pressure of 1.013 bar using a
Langevin thermostat with a damping coefficient of 5 ps1 and a Langevin
piston with a period of 100 fs and a decay of 50 fs. All simulations were
carried out to ~5 ns; for each simulation, the root mean-square deviation
saturated at ~2.5 ns.RESULTS
E236 is located in the N-terminal portion of the b10 strand of
loop C. Previous work on this residue has produced conflict-
ing results. Schreiter et al. (43) reported that replacement of
E236 with aspartate (E236D) abolished radioligand binding,
and electrophysiological responses were reduced to <1% of
that seen for wild-type (WT) receptors, whereas the E236Q
substitution produced functional receptors but reduced the
apparent affinity for agonists and antagonists >20-fold(please note that in their publication, Schreiter et al. refer
to this residue as E235). Furthermore, the E236D receptors
that were synthesized were mostly trapped in intracellular
compartments. On the other hand, Thompson et al. (13)
did not detect any significant difference in [3H]granisetron
affinity relative to WT receptors for E236D receptors. Based
on these results, Schreiter et al. proposed that E236 plays
a significant role in both receptor trafficking and affinity,
whereas Thompson et al. did not propose a role for this
residue. The proposed location of E236 and the conflicting
results concerning the E236D mutation led us to reexamine
this residue.
We examined the interaction of E236D, E236Q, E236N,
and E236A receptors with competitive antagonists. In
agreement with Schreiter et al. (43) and in contrast to
Thompson et al. (13), we find that the E236D mutation abol-
ishes [3H]granisetron binding. Furthermore, using confocal
microscopy to examine the subcellular distribution of recep-
tors, E236D receptors were not expressed on the cell surface
and were trapped in intracellular compartments (Fig. 2), also
in agreement with Schreiter et al. (Thompson et al. did not
examine the subcellular distribution of E236D receptors.).
E236Q, E236N, and E236A receptors were transported
to the cell surface and show small (3- to 8-fold) decreases
in granisetron affinity (WT Kd ¼ 2.2 nM, mutant receptor
Kd ¼ 6–18 nM).Biophysical Journal 98(9) 1847–1855
TABLE 1 Afﬁnity of dTC analogs for mutant and WT 5-HT3Rs
Ligand WT pKi 5 SD E236Q pKi5 SD E236N pKi 5 SD E236A pKi5 SD
dTC 7.205 0.02 6.115 0.05* 5.655 0.06* 6.535 0.07*
tubocurine 7.035 0.03 6.185 0.08* 5.675 0.06* 6.795 .06
chondocurarine 6.635 0.06 5.455 0.07* 5.245 0.04* 6.335 0.04*
metocurine 5.345 0.03 4.395 0.05* 5.435 0.09 6.135 0.07*
O,O-dimethyltubocurine 5.675 0.05 4.465 0.09* 5.085 0.08* 6.475 0.08*
70-O-methylcondocurarine 7.195 0.02 5.675 0.04* 5.205 0.09* 6.665 0.07*
120-O-methylchondocurarine 5.515 0.02 4.455 0.05* 5.065 0.06 5.935 0.05*
Estimates of pKi values were calculated from experimentally determined pIC50 values for the inhibition of [
3H]granisetron binding to WT or mutant receptors
as described in the Materials and Methods section. Errors represent the error determined by the Levenberg-Marquardt regression routine used in the fitting.
Values for the mutant receptors marked with * are statistically different from WT at a 95% confidence level using Student’s t-test.
1850 Nyce et al.We examined the interaction of a panel of dTC analogs
(Fig. 1) with WT and mutant receptors. Table 1 shows esti-
mates of the affinity of WT, E236Q, E236N, and E236A
receptors for the dTC analogs. All three mutations reduced
the affinity for dTC 5- to 35-fold, with the greatest decrease
in affinity observed for the E236N receptor. Fig. 3 shows inhi-
bition curves for dTC, chondocurarine, and 120-O-methyl-
chondocurarine (120-OMCC) for WT, E236Q, and E236N
receptors. Chondocurarine differs from dTC by the presence
of an additional methyl group at the 2N position, whereas
120-OMCC differs from dTC by a second methyl group at
the 2N and replacement of the 12 –OH to a –OCH3 group
(Fig. 1); the latter change is also the only difference between
chondocurarine and 120-OMCC. For WT and E236Q recep-
tors, replacement of the 12 –OH by a –OCH3 group resulted
in a large decrease in apparent affinity relative to dTC and
chondocurarine, whereas the same replacement had only
a small effect on affinity for the E236N receptor. These data
suggest that E236 interacts with the 12 –OH in dTC.
To further examine the interaction of dTC with E236, we
analyzed the effects of substitutions at various positions in
dTC using double-mutant cycle analysis (18). The under-
lying logic of this approach is that if residue x in the binding
site interacts with substituent y on the ligand, then the effect
of mutating x should depend on whether substituent y in the
ligand is changed or not. The free energy of interaction,
DDGint, is calculated from the Ki values as
DDGint ¼ DGWL1 þ DGML2  DGWL2  DGML1 (3)
where DGx ¼ RTlnKix, W is the WT receptor, M is the
mutant receptor, and L1 and L2 are the two ligands beingBiophysical Journal 98(9) 1847–1855compared. The absolute value of DDGint is used in compar-
isons, as the sign of DDGint depends on which ligand is
chosen as L1 and which is chosen as L2. This approach has
been applied to identify points of contact between peptide
toxins and Kþ channels (44,45), AChRs and a-neurotoxins
(46) and dTC analogs (47), and 5-HT3R and granisetron
(16) and dTC (15). jDDGintj valuesR 1 kcal/mol are consis-
tent with a small spatial separation between the residue under
investigation and the portion of the ligand that is altered (48).
Fig. 4 shows mutant cycles examining the effects of
the E236N and E236Q mutations on chondocurarine,
70-OMCC, and 120-OMCC affinity. These cycles examine
the effects of replacement of the –OH group by a –OCH3
group at either the 7 position (the chondocurarine/70-OMCC
cycles) or the 12 position (the chondocurarine/120-OMCC
cycles). The only cycle that shows a jDDGintjR 1 kcal/mol
is the WT/E236N/chondocurarine/120-OMCC cycle, with
jDDGintj ¼ 1.6 5 0.3 kcal/mol. Table 2 gives the results
of 15 different mutant cycles constructed for various WT/
mutant receptor pairs. In all cases where jDDGintj >
1 kcal/mol, the substituent at the 12 position differs between
L1 and L2, whereas for all cases where jDDGintj < 1, the
substituent at this position is the same for the two ligands
in the cycle (either –OH or –OCH3). These data are consis-
tent with E236 making a physical interaction with the
12 position of dTC.DISCUSSION
It is extremely challenging to interpret data from site-directed
mutagenesis studies in terms of protein structure. A numberFIGURE 3 Effects of mutations at E236 on dTC, chon-
docurarine, and 120-O-methylchondoocurine affinity. The
concentration dependence of inhibition of [3H]granisetron
binding to WT, E236Q, and E236N 5-HT3Rs by dTC
(), chondocurarine (:), and 120-OMCC (-) are shown.
Each data point represents the mean 5 SE of three deter-
minations. The solid curves are drawn according to Eq. 1
using log(IC50) values of 6.90 (WT, dTC), 6.33 (WT,
chondocurarine), 5.25 (WT,120-OMCC), 5.81 (E236Q,
dTC), 5.15 (E236Q, chondocurarine), 4.14 (E236Q,
120-OMCC), 5.34 (E236N, dTC), 4.91 (E236N, chon-
docurarine), and 4.76 (E236N,120-OMCC).
FIGURE 4 Double-mutant cycles for WT, E236Q, and E236N receptors
and chondocurarine, 120-OMCC, and 70-OMCC. The interaction coefficient,
DDGint, for each combination of the receptors and ligands was determined
from the Ki values of each ligand for each receptor. The DDGint value of
1.6 5 0.3 kcal/mol for the WT/E236N/chondocurarine/120-OMCC cycle
indicates that an interaction between E236 and the 12 OH of the ligand is
altered by the E236N mutation.
Molecular Ruler and Binding Site Mapping 1851of residues in loops A–F of 5-HT3R have been implicated as
playing potential roles in ligand-receptor interactions (11–
13,15,16,21,22,27,43,49–52). However, cataloging residues
that may interact with ligands is the first step in elucidating
the architecture of the ligand-binding site. In this report,
we focus on E236, which is within loop C in the ligand-
binding domain. Previous work on this residue has produced
conflicting results regarding the effect of the E236D muta-
tion. One group reported that E236D receptors were severely
compromised, with cell-surface expression levels and elec-
trophysiological responses reduced >100-fold relative to
WT (43), whereas the other reported that E236D receptors
had radioligand affinity similar to WT receptors (13). Our
data are consistent with the former and suggest that E236TABLE 2 DDGint values in kcal/mol for various ligand pairings
Ligand pair Differences E23
dTC/metocurine 2N, 7, 12 0
dTC/tubocurine 20N 0
dTC/O,O-DMTC 20N, 7, 12 -0
metocurine/tubocurine 2N, 20N, 7, 12 0
metocurine/O,O-DMTC 2N, 20N -0
O,O-DMTC/tubocurine 7, 12 0
dTC/chondocurarine 2N -0
dTC/70-OMCC 2N, 7 -0
chondocurarine/70-OMCC 7 -0
O,O-DMC/70-OMCC 7, 12 -0
dTC/120-OMCC 2N, 12 0
70-OMCC/120-OMCC 7, 12 0
metocurine/120-OMCC 7 0
chondocurarine/120OMCC 12 0
metocurine/70-OMCC 12 -0
DDGint values were determined for double-mutant cycles using WT and mutant replays a role in proper assembly and/or folding of the
receptor. It is unclear why a conservative replacement
(E/ D) has such a profound effect on receptor assembly
when other replacements (Q, N, and A) do not. We have
made the E236D mutant several different times, sequencing
the entire coding region each time, and obtained the same
result each time. Although the effect is real, and confirms
the independent finding by another group (43), the under-
lying mechanism is unclear.
Residues homologous to E236 in other Cys-loop ligand-
gated ion channels and the AChBP have also been implicated
in ligand-receptor interactions. In the a-subunit of the AChR,
dTC protects cysteine-substituted aD200 (aD200C) from
alkylation (53). In the b-subunit of the GABAAR, bR207
faces into the binding site and stabilizes GABA binding to
the receptor (54). In the Aplysia AChBP, the homologous
residue (D197) forms a salt bridge with the antagonist a-con-
otoxin ImI (33). It is clear that this residue is located in the
ligand-binding domain and plays a role in receptor function.
Double-mutant cycle analysis allows the effects of muta-
tions to be interpreted in terms of specific ligand-receptor
interactions. This type of analysis allows one to determine
which parts of the ligand interact with which residues in
the binding site. Mapping these points of interaction onto
the three-dimensional structure of ligands provides informa-
tion about the spatial orientation of residues in the ligand-
binding site. One can use these distance measurements as
additional constraints in the modeling process and further
refine a model for the binding site.
Our data suggest that E236 makes a physical interaction
with the 12 –OH of dTC. The data are consistent with a direct
physical interaction; however, the effect could be due to
either an interaction between the ligand and the receptor or
a conformational rearrangement in the receptor induced by
the mutation. Although it is not possible a priori to determine
which mechanism applies, there are guidelines one can apply
to discriminate between these two possibilities.6Q DDGint E236N DDGint E236A DDGint
.15 0.2 2.25 0.3 1.95 0.3
.35 0.4 0.35 0.4 0.65 0.3
.25 0.3 1.65 0.3 2.3 5 0.3
.25 0.4 -1.95 0.4 -1.35 0.3
.35 0.3 -0.65 0.4 0.45 0.3
.55 0.5 -1.45 0.4 -1.75 0.3
.25 0.3 0.15 0.3 0.3 5 0.3
.65 0.2 0.65 0.3 0.2 5 0.3
.45 0.3 -0.65 0.3 0.1 5 0.3
.45 0.3 -2.25 0.3 -2.15 0.3
.25 0.3 1.75 0.3 1.5 5 0.2
.85 0.3 2.35 0.3 1.3 5 0.2
.15 0.3 -0.55 0.4 -0.45 0.3
.55 0.4 1.75 0.4 1.2 5 0.3
.75 0.2 -2.85 0.3 -1.75 0.3
ceptors, and the indicated ligand pairs from the Ki values according to Eq. 3.
Biophysical Journal 98(9) 1847–1855
1852 Nyce et al.If there is a direct interaction between part of the ligand
and a specific residue in the receptor, they must be physically
close. In a study of barnase/barstar interactions, Schreiber
and Fersht (48) showed that jDDGintj values R 1 kcal/mol
were correlated with the residues in question being within
% 4 A˚ of each other, whereas lower free energies of interac-
tion were correlated with greater spatial separation. The
larger the jDDGintj value, the more likely it is that the effect
is due to a direct physical interaction with the region of the
ligand that has been modified. We employ jDDGintj R 1
as our cutoff for identifying an interaction.
On the other hand, if the observed coupling is due to
a conformational rearrangement in the receptor induced by
the mutation, it is unlikely that the coupling would be limited
to a single portion of the ligand. Analysis of 15 different
mutant cycles for each receptor employing seven different
dTC analogs shows that the coupling localizes to a single
part of dTC (the 12 –OH), which is what one would expect
for disruption of a specific interaction. Furthermore, cycles
employing two very different substitutions at the same posi-
tion (E236N and E236A) show the same coupling. It is
unlikely that these two mutations would produce exactly
the same conformational change in the receptor. Thus, the
data are most consistent with the notion that E236 is in close
physical contact with the 12 –OH of dTC.
The mutant cycles indicate coupling between E236 and
the 12 –OH of dTC for E236N and E236A, but not
E236Q, receptors. WT and E236Q receptors show a large
(30- to 60-fold) decrease in affinity relative to dTC for those
compounds with a 12 –OCH3 (metocurine, OODMC, and
120-OMCC), whereas E236N and E236A receptors show
smaller decreases (<4-fold) for the same changes. The
N and A side chains have smaller volumes than either E or
Q, with N being 20.7 A˚3 smaller than E, A being 49.8 A˚3
smaller than E, and Q being 5.5 A˚3 larger than E (55). Intro-
duction of the bulky –OCH3 substitution may create a steric
clash with the E and Q side chains, but not the smaller N and
A side chains, explaining the differential effects of the muta-
tions on analogs with a 12 –OH versus a 12 –OCH3.
The sign of the DDGint values for the mutant cycles (posi-
tive for cycles in which the –OH is replaced by –OCH3;
negative for the converse) indicates that replacement of the
–OH with –OCH3 either removes a favorable interaction or
creates an unfavorable one. The jDDGintj values obtained
from the E236A and E236N cycles are 1.3–2.8 kcal/mol,
within the range for a hydrogen bond. Both E and Q can
make a hydrogen bond with 12 –OH; however, the E236A
and E236N mutants cannot, due to either their chemical
nature (E236A) or smaller size (E236N). Conversion of the
–OH to –OCH3 could disrupt this interaction and affect
WT and E236Q receptors equally, consistent with the fact
that the DDGint values for E236Q cycles do not meet our
criteria for significance.
However, all mutants show a reduction in affinity for dTC
relative to WT receptors. The smallest reduction in affinity isBiophysical Journal 98(9) 1847–1855seen for the E236A receptor, which is not consistent with a
hydrogen bond between E236 and the 12 –OH. Rather
than the removal of a favorable interaction (e.g., a hydrogen
bond), it may be the introduction of an unfavorable steric
interaction by conversion of the –OH to the bulkier
–OCH3 substituent that the mutant cycle analysis detects.
E236 and E236Q are approximately the same size and
exhibit similar differential sensitivity to –OCH3 versus
–OH substituents, whereas the smaller E236N and E236A
do not. This appears to be a more reasonable interpretation
of the results. However, regardless of the underlying mech-
anism for the coupling, the double-mutant cycle analysis
clearly supports the notion that E236 and the 12 –OH are
in close physical contact.
Previous work in our laboratory suggests that N128 (loop
A, (þ)-face of the binding site) interacts with the 20N and
R92 (loop D, ()-face) interacts with the 2N of dTC (15).
Another group has proposed that N128 faces away from
the ligand-binding site (56). This conclusion was based on
the observation that the N128A mutation has no effect on
[3H]granisetron affinity, which was interpreted to mean
that this residue played no role in antagonist-receptor interac-
tion. We also reported that although the N128A mutation has
no effect on [3H]granisetron affinity, it does have a significant
effect on dTC affinity (15). This formed the basis for the
double-mutant cycle analysis, which led to the conclusion
that N128 interacts with the 20N of dTC. Since the conclu-
sion of the other group was based on a negative result ob-
tained with the use of a single ligand, and ours was based
on the use of multiple ligands and a demonstrated effect of
the mutation on antagonist-receptor interactions, we believe
our placement of N128 as forming part of and facing into the
binding site is correct.
The identification of a third residue (E236, within loop C,
(þ)-face) that interacts with a specific portion of dTC gives
us an opportunity to delineate the spatial relationships among
these three residues in the binding site. dTC is a constrained
molecule of known three-dimensional structure (57,58). MD
simulations of dTC in solution show that the 2N-20N distance
during a 5 ns simulation is relatively constant. The two nitro-
gens are separated by 10.45 0.2 A˚ during the entire simu-
lation period (data not shown), supporting the notion that
dTC is a rigid molecule. By mapping residues in the binding
site to the points of interaction with dTC, we can determine
spatial relationships between specific residues. Assuming
that atoms are hard spheres (with dimensions determined
by their van der Waals radii (59)) that make close contact
with each other, we obtain estimates of the distances between
the guanidinium of R92, the amide of N128, and the carbox-
ylate of E236. The N128:E236 distance is ~9 A˚, the
N128:R92 distance is ~16 A˚, and the R92:E238 distance is
~12 A˚. These distances become additional restraints in the
homology modeling process, allowing refinement of the
model with experimental data. The refined homology model
derived with the use of these experimentally obtained
FIGURE 5 Representation of dTC in the 5-HT3R binding site looking
down from the top (i.e., facing the synapse) of the receptor. A model of the
dTC/5-HT3R complex was obtained using MD calculations as described
in the text. Residues used in the mapping (R92, N128, and E236) are shown
in standard colors, and additional residues implicated in receptor/dTC
interactions are shown in cyan ((þ)-face) or green (()-face)). Note that
R92 is close to the 2N, N128 is close to the 20N, and E236 is close to the
12 –OH.
Molecular Ruler and Binding Site Mapping 1853distance restraints are then used for ligand docking with
AutoDock.
One weakness of homology modeling is that although it
does a good job in predicting the main-chain conformation,
it is weaker for side-chain conformation (60). Although
MD simulations are far more computationally intensive
than homology modeling and ligand docking, they can be
used to refine the static structures obtained by homology
modeling and ligand docking through relaxation to a more
thermodynamically stable conformation governed by inter-
actions within the protein, between the protein and the
ligand, and between the complex and its environment. This
approach has been used with the AChBP (61,62), AChR
(63–65), and GlyR (66). Eriksson and Roux (67) performed
homology modeling of the Shaker Kþ channel followed by
MD-driven docking of agitoxin2 with imposition of spatial
relationships/restraints obtained from double-mutant cycle
analysis (45). The resulting simulations produced channel-
toxin complexes that were in strong agreement with the
experimental data.
We used the dTC-receptor complex obtained from dock-
ing simulations, using the model refined by employing the
distance restraints described above as the initial starting state,
and performed MD simulations for 5 ns. The structures
relaxed to a stable state within 2.5 ns, and the stable confor-
mation is shown in Fig. 5. Also shown in the figure are the
locations of five other residues that have been implicated
in 5-HT3R/dTC interactions on the basis of effects of muta-
tions on dTC affinity: one on the (þ)-face (D229, loop C)
(21)) and four on the ()-face (W90, loop D (27); Y141,
loop E (52); Y153, loop E (52); and I207, loop F (22)).
Examination of this complex shows that most of the residues
cluster around docked dTC. Furthermore, R92, N128, and
E236 are positioned to make the interactions with dTC
predicted from experimental data, indicating that this
approach can provide a more realistic picture of the ligand-
receptor complex than the more static docking procedures
used previously.
This study shows the power of combining double-mutant
cycle analysis with the use of a rigid ligand to probe ligand-
receptor interactions in such a way as to allow different
portions of the ligand to be mapped onto specific residues
in the receptor. This approach is applicable to any ligand-
receptor system in which a conformationally constrained
ligand that can be modified is employed. The ligand can be
either a small-molecule compound like dTC, with various
substituents, or recombinant peptide toxins such as scorpion
toxins and conotoxins, which assume fairly compact struc-
tures constrained by disulfide bonds. These peptide toxins
target a number of ion channel families, including voltage-
gated Kþ channels (e.g., agitoxin2 (45)), voltage-gated
Naþ channels (e.g., scorpion b-toxins (68)), voltage-gated
Ca2þ channels (e.g., u-conotoxins (69)), and various nico-
tinic AChR subtypes (e.g., a-conotoxins (70)). In conjunc-
tion with molecular modeling studies, this molecular rulerapproach provides an iterative process for modeling and
experimentally testing models, which in turn can accelerate
the process of mapping the three-dimensional architecture
of a ligand-binding domain. It provides an alternative to
resonance energy-transfer techniques to obtain spatial infor-
mation in macromolecular complexes, and is advantageous
because it does not require the use of reporter groups, which
may alter receptor function when inserted into the ligand-
binding site. Extensive mapping of the relative positions of
residues in the binding site should allow the elucidation of
the architecture of the ligand-binding domain, and thus
provide useful information for the design of novel pharmaco-
logical agents with both high affinity and high specificity for
use as therapeutic agents.
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